12M Price Target
$55
-33% from $82.50
Intrinsic Value
$54
-35% upside
Thesis Confidence
5/10
Moderate
Bear Case
$34
Growth -3pp, WACC +1.5pp, terminal growth -0.5pp…
Base Case
$54
Current assumptions from EDGAR data
Bull Case
$78
Growth +3pp, WACC -1pp, terminal growth +0.5pp…
What Would Kill the Thesis
| Pillar | Invalidating Facts | P(Invalidation) |
|---|
| procedure-volume-adoption |
Two consecutive quarters of Edwards reporting structural heart procedure growth materially below the level needed to support consensus sales growth (e.g., THV/TMTT procedure or sales growth falling to low-single digits or declining year over year).; Management cuts 12-24 month structural heart growth guidance because underlying procedure growth, site activation, or patient referral volumes are weaker than expected.; Independent market data or competitor disclosures show Edwards is losing enough share in core structural heart categories that procedure market growth no longer translates into Edwards sales growth. |
True 38% |
| moat-durability-structural-heart |
A major competitor demonstrates sustained share gains against Edwards in core structural heart markets across multiple geographies or launches a clearly superior product with better clinical, ease-of-use, or economic outcomes.; Edwards' structural heart gross margin or segment operating margin compresses materially and persistently due to pricing pressure, mix deterioration, or increased competitive spend.; New clinical data, guideline changes, or reimbursement decisions reduce the relative advantage of Edwards' platforms and make hospital purchasing meaningfully more contestable. |
True 42% |
| valuation-premium-justified |
Pipeline programs that underpin optionality are delayed, miss pivotal endpoints, receive restrictive labels, or fail to show commercially meaningful differentiation.; Management signals that margin resilience is weaker than expected through lower long-term margin targets, higher operating expense requirements, or reduced free-cash-flow conversion.; Even after incorporating updated guidance and pipeline outcomes, consensus earnings/cash-flow estimates do not inflect upward enough to support the premium multiple. |
True 47% |
| estimate-revisions-and-sentiment |
Consensus EPS/revenue estimates continue to move down over successive months or quarters rather than stabilizing or revising upward.; Sell-side price target dispersion remains wide or widens further after earnings, indicating low conviction and fragile underwriting of the outlook.; Post-earnings stock reactions remain negative despite in-line results, signaling sentiment is not repaired and expectations are vulnerable. |
True 44% |
Source: Risk analysis
Exhibit: Financial Snapshot
| Period | Revenue | Net Income | EPS |
|---|
| FY2024 |
$6.1B |
$1.1B |
$1.83 |
| FY2024 |
$6.1B |
$1.1B |
$1.83 |
| FY2025 |
$6.1B |
$1.1B |
$1.83 |
Source: SEC EDGAR filings
Key Metrics Snapshot
SNAPSHOT
Price
$81.22
Mar 22, 2026
Gross Margin
78.0%
FY2025
Rev Growth
+11.5%
Annual YoY
EPS Growth
-73.7%
Annual YoY
Overall Signal Score
55 / 100
Fundamental quality remains strong, but valuation and Q3 momentum temper the setup.
Bullish Signals
6
ROIC 13.1% > WACC 8.2%, FCF margin 22.0%, current ratio 3.72, and shares outstanding fell to 580.7M.
Bearish Signals
5
PE 45.1x, EV/EBITDA 32.1x, and Q3 operating income slipped to $307.1M from $411.2M in Q2.
Data Freshness
≈81 days
Latest audited FY2025 EDGAR data; live market price as of Mar 22, 2026.
Exhibit: Valuation Summary
| Method | Fair Value | vs Current |
|---|
| DCF (5-year) |
$54 |
-33.5% |
| Bull Scenario |
$78 |
-4.0% |
| Bear Scenario |
$34 |
-58.1% |
| Monte Carlo Median (10,000 sims) |
$58 |
-28.6% |
Source: Deterministic models; SEC EDGAR inputs
Executive Summary
Executive Summary overview. Recommendation: Short · 12M Price Target: $55 (-33% from $82.50) · Intrinsic Value: $54 (-35% upside).
ASSUMPTIONS SCORED
0
0 high-conviction
NUMBER REGISTRY
0
0 verified vs EDGAR
QUALITY SCORE
0%
12-test average
Detailed valuation analysis → val tab
Risk assessment → risk tab
Financial analysis → fin tab
Variant Perception & Thesis
Variant Perception & Thesis overview. Price: $81.22 (Mar 22, 2026) · Market Cap: ~$47.9B.
Price
$81.22
Mar 22, 2026
Thesis Pillars
THESIS ARCHITECTURE
1. Procedure-Volume-Adoption Catalyst
Can Edwards sustain procedure-driven sales growth in structural heart therapies at a level that supports the market's expectations over the next 12-24 months. Primary value driver identified as procedure-driven demand for core structural heart products, especially transcatheter valve therapies, with confidence 0.82. Key risk: Base DCF still values the shares materially below the current price, implying current expectations may already assume stronger procedure growth than the modeled base case. Weight: 28%.
2. Moat-Durability-Structural-Heart Catalyst
Is Edwards' competitive advantage in structural heart durable enough to preserve above-peer growth and healthy margins, or is the market becoming more contestable. EW is often implicitly framed as a quality/defensive medtech franchise, which could indicate durable clinical positioning, switching costs, or procedural know-how. Key risk: The company is being framed against a crowded large-cap medtech peer group including Medtronic, Intuitive Surgical, Abbott, Boston Scientific, Stryker, and Siemens Healthineers, implying meaningful competitive intensity. Weight: 24%.
3. Valuation-Premium-Justified Catalyst
Does EW deserve to trade above base and even bull-case DCF values because of pipeline optionality, margin resilience, or premium-franchise characteristics not captured in the base model. Relative valuation and consensus targets imply modest upside or near-fair value rather than severe overvaluation. Key risk: Base DCF per-share value is 53.77 versus current price 81.22, implying roughly 35% overvaluation on that framework. Weight: 22%.
4. Estimate-Revisions-And-Sentiment Catalyst
Are earnings estimates, price targets, and sentiment indicators stabilizing in a way that could support a re-rating, or is target dispersion signaling fragile expectations and downside risk. One contradiction notes that analyst target dispersion may be interpreted as a setup more consistent with gradual re-rating in the historical view. Key risk: Another contradiction interprets analyst target dispersion as fragility and downside risk in the bear view. Weight: 14%.
5. Share-Count-And-Capital-Allocation Thesis Pillar
Is capital allocation genuinely accretive on a per-share basis once stock-based compensation and any compensation-related issuance are fully accounted for. Diluted share count has trended down from 609.4M at 2023-12-31 to 585.8M at 2025-12-31, which is a modest tailwind to per-share value. Key risk: Compensation-related equity issuance is flagged as a potential dilution concern. Weight: 12%.
Key Value Driver: Procedure-driven demand for Edwards Lifesciences' core structural heart products, especially transcatheter valve therapies, is the main valuation driver. Because the business appears highly concentrated and management is signaling confidence in sustained sales growth, changes in procedure volumes and adoption rates likely have the largest impact on revenue growth and the stock.
KVD
Details pending.
Unique Signals (Single-Vector Only)
TRIANGULATION
ASSUMPTIONS SCORED
0
0 high-conviction
NUMBER REGISTRY
0
0 verified vs EDGAR
QUALITY SCORE
0%
12-test average
Exhibit: Multi-Vector Convergences (3)
| Confidence |
|---|
| HIGH |
| MODERATE |
| HIGH |
Source: Methodology Triangulation Stage (5 isolated vectors)
Cross-Vector Contradictions (4): The triangulation stage identified conflicting signals across independent analytical vectors:
- ? vs?: Conflicting data
- ? vs?: Conflicting data
- ? vs?: Conflicting data
- ? vs?: Conflicting data
See risk analysis → risk tab
Valuation
Valuation overview. DCF Fair Value: $53 (5-year projection) · Enterprise Value: $45.6B (DCF) · WACC: 8.2% (CAPM-derived).
DCF Fair Value
$54
5-year projection
Enterprise Value
$45.6B
DCF
Terminal Growth
4.0%
assumption
DCF vs Current
$54
vs $81.22
Price / Earnings
45.1x
FY2025
Price / Sales
7.9x
FY2025
Bear Case
$34
Growth -3pp, WACC +1.5pp, terminal growth -0.5pp…
Base Case
$54
Current assumptions from EDGAR data
Bull Case
$78
Growth +3pp, WACC -1pp, terminal growth +0.5pp…
MC Median
$58
10,000 simulations
5th Percentile
$16
downside tail
95th Percentile
$281
upside tail
P(Upside)
-34.5%
vs $81.22
Exhibit: DCF Assumptions
| Parameter | Value |
|---|
| Revenue (base) |
$6.1B (USD) |
| FCF Margin |
22.0% |
| WACC |
8.2% |
| Terminal Growth |
4.0% |
| Growth Path |
11.6% → 9.8% → 8.7% → 7.8% → 6.9% |
| Template |
mature_cash_generator |
Source: SEC EDGAR XBRL; computed deterministically
Exhibit: Reverse DCF — What the Market Implies
| Implied Parameter | Value to Justify Current Price |
|---|
| Implied Growth Rate |
20.6% |
| Implied Terminal Growth |
5.7% |
Source: Market price $81.22; SEC EDGAR inputs
Exhibit: WACC Derivation (CAPM)
| Component | Value |
|---|
| Beta |
0.72 |
| Risk-Free Rate |
4.25% |
| Equity Risk Premium |
5.5% |
| Cost of Equity |
8.2% |
| D/E Ratio (Market-Cap) |
0.01 |
| Dynamic WACC |
8.2% |
Source: 753 trading days; 753 observations
Exhibit: Kalman Growth Estimator
| Metric | Value |
|---|
| Current Growth Rate |
44.1% |
| Growth Uncertainty |
±14.6pp |
| Observations |
10 |
| Year 1 Projected |
35.7% |
| Year 2 Projected |
29.1% |
| Year 3 Projected |
23.8% |
| Year 4 Projected |
19.5% |
| Year 5 Projected |
16.1% |
Source: SEC EDGAR revenue history; Kalman filter
Exhibit: Monte Carlo Fair Value Range (10,000 sims)
Source: Deterministic Monte Carlo model; SEC EDGAR inputs
Exhibit: Valuation Multiples Trend
Source: SEC EDGAR XBRL; current market price
DCF Adjustment ($54)
28.73
See financial analysis → fin tab
See risk assessment → risk tab
Financial Analysis
Financial Analysis overview. Gross Margin: 78.0% (FY2025) · Op Margin: 20.8% (FY2025) · Net Margin: 17.7% (FY2025).
Exhibit: Revenue Trend (Annual)
Source: SEC EDGAR 10-K filings
Exhibit: Net Income Trend (Annual)
Source: SEC EDGAR 10-K filings
Gross Margin
78.0%
FY2025
Current Ratio
3.72x
Latest filing
Debt/Equity
0.06x
Latest filing
Interest Cov
71.8x
Latest filing
Rev Growth
+11.5%
Annual YoY
NI Growth
-74.3%
Annual YoY
EPS Growth
1.8%
Annual YoY
TOTAL DEBT
$598M
LT: $598M, ST: —
NET DEBT
$-2.3B
Cash: $2.9B
INTEREST EXPENSE
$18M
Annual
DEBT/EBITDA
0.5x
Using operating income as proxy
INTEREST COVERAGE
71.8x
OpInc / Interest
Exhibit: Net Income Trend
Source: SEC EDGAR XBRL filings
Exhibit: Free Cash Flow Trend
Source: SEC EDGAR XBRL filings
Exhibit: Return on Equity Trend
Source: SEC EDGAR XBRL filings
Exhibit: Financial Model (Income Statement)
| Line Item | FY2024 | FY2024 | FY2024 | FY2024 | FY2025 |
|---|
| Revenues |
$1.3B |
$1.4B |
$1.4B |
$5.4B |
$6.1B |
| Gross Profit |
$1.0B |
$1.1B |
$1.1B |
$4.3B |
$4.7B |
| Net Income |
$352M |
$366M |
$3.1B |
$4.2B |
$1.1B |
| EPS (Diluted) |
$0.58 |
$0.61 |
$5.13 |
$6.97 |
$1.83 |
| Gross Margin |
78.4% |
79.9% |
80.6% |
79.5% |
78.0% |
| Net Margin |
26.5% |
26.7% |
226.7% |
76.7% |
17.7% |
Source: SEC EDGAR XBRL filings (USD)
Exhibit: Debt Composition
| Component | Amount | % of Total |
|---|
| Long-Term Debt |
$598M |
100% |
| Cash & Equivalents |
($2.9B) |
— |
| Net Debt |
$-2.3B |
— |
Source: SEC EDGAR XBRL filings
Exhibit: Debt Level Trend
Source: SEC EDGAR XBRL filings
See earnings scorecard → scorecard tab
Street Expectations
Street Expectations overview. Current Price: $81.22 (Mar 22, 2026) · Market Cap: ~$47.9B · DCF Fair Value: $54 (our model).
Current Price
$81.22
Mar 22, 2026
DCF Fair Value
$54
our model
vs Current
-34.8%
DCF implied
Our Quantitative View
DETERMINISTIC
DCF Model: $54 per share
Monte Carlo: $58 median (10,000 simulations, P(upside)=33%)
Reverse DCF: Market implies 20.6% growth to justify current price
Exhibit: Valuation Multiples vs Street
| Metric | Current |
|---|
| P/E |
45.1 |
| P/S |
7.9 |
| FCF Yield |
2.8% |
Source: SEC EDGAR; market data
See variant perception & thesis → thesis tab
Earnings Scorecard
Earnings Scorecard overview. Latest EPS: $1.83 (2025-12-31) · Quarters Available: 12 (EDGAR XBRL) · YoY EPS Growth: +181.5%.
Latest EPS
$1.83
2025-12-31
Quarters Available
12
EDGAR XBRL
Exhibit: EPS Trend (Annual)
Source: SEC EDGAR XBRL filings
Institutional Forward EPS (Est. 2027): $3.15 — independent analyst estimate for comparison against our projections.
LATEST EPS
$0.50
Q ending 2025-09
AVG EPS (8Q)
$1.14
Last 8 quarters
EPS CHANGE
$1.83
vs year-ago quarter
TTM EPS
$6.80
Trailing 4 quarters
Exhibit: EPS History (Quarterly)
| Period | EPS | YoY Change | Sequential |
|---|
| 2023-03 |
$1.83 |
— |
— |
| 2023-06 |
$1.83 |
— |
-10.7% |
| 2023-09 |
$1.83 |
— |
+26.0% |
| 2023-12 |
$1.83 |
— |
-3.2% |
| 2024-03 |
$1.83 |
+3.6% |
-4.9% |
| 2024-06 |
$1.83 |
+22.0% |
+5.2% |
| 2024-09 |
$1.83 |
+714.3% |
+741.0% |
| 2024-12 |
$1.83 |
+6.6% |
-87.3% |
| 2025-03 |
$1.83 |
+5.2% |
-6.2% |
| 2025-06 |
$1.83 |
-8.2% |
-8.2% |
| 2025-09 |
$1.83 |
-90.3% |
-10.7% |
| 2025-12 |
$1.83 |
+181.5% |
+266.0% |
Source: SEC EDGAR XBRL filings
Exhibit: Quarterly Earnings History
| Quarter | EPS (Diluted) | Revenue | Net Income |
|---|
| Q2 2023 |
$1.83 |
$6.1B |
$1073.5M |
| Q3 2023 |
$1.83 |
$6.1B |
$1073.5M |
| Q1 2024 |
$1.83 |
$6.1B |
$1073.5M |
| Q2 2024 |
$1.83 |
$6.1B |
$1073.5M |
| Q3 2024 |
$1.83 |
$6.1B |
$1.1B |
| Q1 2025 |
$1.83 |
$6.1B |
$1073.5M |
| Q2 2025 |
$1.83 |
$6.1B |
$1073.5M |
| Q3 2025 |
$1.83 |
$6.1B |
$1073.5M |
Source: SEC EDGAR XBRL filings
EPS Cross-Validation: Our computed TTM EPS ($6.80) differs from institutional survey EPS for 2024 ($2.43) by +180%. This divergence may indicate cumulative vs. quarterly confusion in EDGAR data.
See financial analysis → fin tab
See street expectations → street tab
Edwards Lifesciences (EW) | Signals
Signals overview. Overall Signal Score: 55 / 100 (Fundamental quality remains strong, but valuation and Q3 momentum temper the setup.) · Long Signals: 6 (ROIC 13.1% > WACC 8.2%, FCF margin 22.0%, current ratio 3.72, and shares outstanding fell to 580.7M.) · Short Signals: 5 (PE 45.1x, EV/EBITDA 32.1x, and Q3 operating income slipped to $307.1M from $411.2M in Q2.).
Overall Signal Score
55 / 100
Fundamental quality remains strong, but valuation and Q3 momentum temper the setup.
Bullish Signals
6
ROIC 13.1% > WACC 8.2%, FCF margin 22.0%, current ratio 3.72, and shares outstanding fell to 580.7M.
Bearish Signals
5
PE 45.1x, EV/EBITDA 32.1x, and Q3 operating income slipped to $307.1M from $411.2M in Q2.
Data Freshness
≈81 days
Latest audited FY2025 EDGAR data; live market price as of Mar 22, 2026.
Non-obvious takeaway. The important signal is not that EW is still growing, but that profitability momentum has cooled faster than revenue. Implied revenue rose to $1.5552B in Q3 2025, yet operating income fell to $307.1M from $411.2M in Q2, which suggests the market is paying for an earnings reacceleration that has not yet shown up in the quarterly operating line.
Alternative Data Signals: Sparse / Not Yet Confirmed
ALT DATA [UNVERIFIED]
We do not have a populated alternative-data series for EW in this spine, so job postings, web traffic, app-download trends, and patent filings are all . That is a meaningful limitation because for a med-tech franchise like Edwards, those signals can help separate true procedure demand from timing noise in quarterly results.
Cross-checking against the audited 2025 10-K, the reported business still showed 11.5% revenue growth and 78.0% gross margin, which means the core franchise is not obviously breaking. But without third-party channel checks we cannot tell whether the Q3 operating income step-down to $307.1M reflects temporary investment or a demand slowdown, so the alternative-data vacuum lowers confidence in near-term inflection timing.
What we would monitor next is whether hiring in field sales, R&D, and manufacturing support accelerates, whether physician-portal traffic rises, and whether patent activity around structural heart or transcatheter platforms remains active; none of that was provided here, so the signal remains incomplete.
Retail and Institutional Sentiment: Constructive, Not Euphoric
SENTIMENT
Institutional sentiment is constructive but measured. The independent survey assigns EW a Safety Rank of 3, Timeliness Rank of 3, Technical Rank of 3, Financial Strength of B++, Earnings Predictability of 100, and Price Stability of 55. That profile says institutions view the name as high quality and relatively stable, but not a momentum favorite or a deep value opportunity.
On the forward side, the same survey points to $2.60 EPS for 2025, $2.90 for 2026, and $3.15 for 2027, with a $110.00-$165.00 3-5 year target range. Relative to the live price of $81.22 as of Mar. 22, 2026, that indicates institutional models still see room if execution holds; however, the negative Alpha of -0.20 and Beta of 1.00 imply investors should not expect the stock to trade as a defensive bond proxy. Retail sentiment is because no social or positioning feed was supplied.
Exhibit 1: EW Signal Dashboard
| Category | Signal | Reading | Trend | Implication |
|---|
| Growth |
Revenue |
+11.5% YoY; implied revenue moved from $1.4116B in Q1 to $1.5344B in Q2 and $1.5552B in Q3… |
Positive but decelerating |
Top-line remains healthy, but the pace is not strong enough to justify multiple expansion on growth alone. |
| Profitability |
Gross margin / operating margin |
78.0% gross margin; 20.8% operating margin… |
Stable gross, softer operating |
The gross line remains elite, but SG&A of $2.09B keeps operating leverage from fully flowing through. |
| Operating momentum |
Q3 operating income |
$307.1M vs $411.2M in Q2 |
Weakening |
This is the clearest near-term signal to watch; sustained weakness would pressure the thesis. |
| Balance sheet |
Liquidity / leverage |
Current ratio 3.72; debt to equity 0.06; total liabilities to equity 0.32… |
Strong |
Low distress risk supports continued investment flexibility and reduces balance-sheet downside. |
| Cash generation |
OCF / FCF |
Operating cash flow $1.5952B; free cash flow $1.335B; FCF margin 22.0% |
Strong |
Cash conversion is robust and helps offset the premium valuation. |
| Valuation |
Multiples / DCF gap |
PE 45.1x; EV/EBITDA 32.1x; DCF base value $53.77 vs live price $81.22… |
Expensive |
The main downside risk is multiple compression if growth or margins miss. |
| Capital allocation |
Share count / capex |
Shares outstanding fell from 587.9M to 580.7M; CapEx $260.2M… |
Supportive |
Per-share compounding is helped by share reduction and disciplined capital intensity. |
| Forward guide |
2026 guidance |
Sales growth 8% to 10%; EPS $2.90 to $3.05… |
Constructive |
Guidance gives bulls a path, but the current price already discounts a good portion of it. |
Source: Company FY2025 10-K (SEC EDGAR); Mar 22, 2026 market data; deterministic ratios
| Metric | Value |
|---|
| EPS |
$2.60 |
| EPS |
$2.90 |
| EPS |
$3.15 |
| EPS |
$110.00-$165.00 |
| Fair Value |
$81.22 |
| Alpha of |
-0.20 |
Exhibit: Piotroski F-Score — 5/9 (Moderate)
| Criterion | Result | Status |
|---|
| Positive Net Income |
✓ |
PASS |
| Positive Operating Cash Flow |
✗ |
FAIL |
| ROA Improving |
✓ |
PASS |
| Cash Flow > Net Income (Accruals) |
✗ |
FAIL |
| Declining Long-Term Debt |
✗ |
FAIL |
| Improving Current Ratio |
✗ |
FAIL |
| No Dilution |
✓ |
PASS |
| Improving Gross Margin |
✓ |
PASS |
| Improving Asset Turnover |
✓ |
PASS |
Source: SEC EDGAR XBRL; computed deterministically
Exhibit: Altman Z-Score — 3.03 (Safe Zone)
| Component | Value |
|---|
| Working Capital / Assets (×1.2) |
0.360 |
| Retained Earnings / Assets (×1.4) |
0.000 |
| EBIT / Assets (×3.3) |
0.092 |
| Equity / Liabilities (×0.6) |
3.077 |
| Revenue / Assets (×1.0) |
0.443 |
| Z-Score |
SAFE 3.03 |
Source: SEC EDGAR XBRL; Altman (1968) formula
Exhibit: Beneish M-Score (5-Variable)
| Component | Value | Assessment |
|---|
| M-Score |
-1.80 |
Unlikely Unlikely Manipulator |
| Threshold |
-1.78 |
Above = likely manipulation |
Source: SEC EDGAR XBRL; 5-variable Beneish model
Biggest risk. Valuation is the obvious caution flag: EW trades at 45.1x PE and 32.1x EV/EBITDA, while the deterministic DCF fair value is only $53.77 versus a live price of $81.22. That is a 53.4% premium to base value, so any sustained weakness in quarterly operating income could trigger meaningful multiple compression.
Aggregate signal picture. Fundamentals are still high quality: ROIC of 13.1% remains above WACC of 8.2%, and free cash flow reached $1.335B with a 22.0% FCF margin. However, the price already reflects a demanding outcome because it sits above the $53.77 DCF base case and only modestly below the $78.30 bull case, so the signal set is constructive on business quality but cautious on near-term upside.
No immediate red flags detected in earnings quality.
We are Neutral-to-slightly Short on EW from a signals perspective. Our core claim is that the business still earns above its cost of capital, with ROIC at 13.1% versus WACC at 8.2%, but the stock’s 45.1x PE leaves too little margin of safety at $82.50 and above the $53.77 DCF base value. We would turn Long only if quarterly operating income reaccelerates back above the $411.2M Q2 level while management sustains $2.90-$3.05 EPS guidance; we would turn Short if operating income stays near or below the $307.1M Q3 level.
See risk assessment → risk tab
See Financial Analysis → fin tab
What Breaks the Thesis
What Breaks the Thesis overview. CURRENT RATIO: 3.7x · INTEREST COV: 71.8x · NET MARGIN: 17.7%.
TOTAL DEBT
$598M
LT: $598M, ST: —
NET DEBT
$-2.3B
Cash: $2.9B
INTEREST EXPENSE
$18M
Annual
DEBT/EBITDA
0.5x
Using operating income as proxy
INTEREST COVERAGE
71.8x
OpInc / Interest
Exhibit: Kill File — 5 Thesis-Breaking Triggers
| Pillar | Invalidating Facts | P(Invalidation) |
|---|
| procedure-volume-adoption |
Two consecutive quarters of Edwards reporting structural heart procedure growth materially below the level needed to support consensus sales growth (e.g., THV/TMTT procedure or sales growth falling to low-single digits or declining year over year).; Management cuts 12-24 month structural heart growth guidance because underlying procedure growth, site activation, or patient referral volumes are weaker than expected.; Independent market data or competitor disclosures show Edwards is losing enough share in core structural heart categories that procedure market growth no longer translates into Edwards sales growth. |
True 38% |
| moat-durability-structural-heart |
A major competitor demonstrates sustained share gains against Edwards in core structural heart markets across multiple geographies or launches a clearly superior product with better clinical, ease-of-use, or economic outcomes.; Edwards' structural heart gross margin or segment operating margin compresses materially and persistently due to pricing pressure, mix deterioration, or increased competitive spend.; New clinical data, guideline changes, or reimbursement decisions reduce the relative advantage of Edwards' platforms and make hospital purchasing meaningfully more contestable. |
True 42% |
| valuation-premium-justified |
Pipeline programs that underpin optionality are delayed, miss pivotal endpoints, receive restrictive labels, or fail to show commercially meaningful differentiation.; Management signals that margin resilience is weaker than expected through lower long-term margin targets, higher operating expense requirements, or reduced free-cash-flow conversion.; Even after incorporating updated guidance and pipeline outcomes, consensus earnings/cash-flow estimates do not inflect upward enough to support the premium multiple. |
True 47% |
| estimate-revisions-and-sentiment |
Consensus EPS/revenue estimates continue to move down over successive months or quarters rather than stabilizing or revising upward.; Sell-side price target dispersion remains wide or widens further after earnings, indicating low conviction and fragile underwriting of the outlook.; Post-earnings stock reactions remain negative despite in-line results, signaling sentiment is not repaired and expectations are vulnerable. |
True 44% |
| share-count-and-capital-allocation |
Diluted share count is flat to up year over year despite meaningful buybacks, showing repurchases are largely offsetting stock-based compensation and issuance.; Net buyback yield after stock-based compensation is de minimis or negative, indicating capital return is not truly accretive on a per-share basis.; The company deploys capital toward acquisitions, compensation-related issuance, or other uses that reduce free-cash-flow-per-share growth relative to reported aggregate free cash flow. |
True 33% |
Source: Methodology Why-Tree Decomposition
Exhibit: Debt Composition
| Component | Amount | % of Total |
|---|
| Long-Term Debt |
$598M |
100% |
| Cash & Equivalents |
($2.9B) |
— |
| Net Debt |
$-2.3B |
— |
Source: SEC EDGAR XBRL filings
Exhibit: Debt Level Trend
Source: SEC EDGAR XBRL filings
Anchoring Risk: Dominant anchor class: UNANCHORED (100% of leaves). High concentration on a single anchor type increases susceptibility to systematic bias.
Why-Tree Gate Warnings:- ANCHORED+PLAUSIBLE = 0% (threshold: >=50%)
Company History
Company History overview. Documented FYs: 15 (FY2011-FY2025) · Latest Filing: N/A (SEC EDGAR) · Filing Count: 0 (Current fact store).
Documented FYs
15
FY2011-FY2025
Latest Filing
N/A
SEC EDGAR
Filing Count
0
Current fact store
Coverage Window
FY2011-FY2025
Verified history floor
Deterministic timeline floor: 15 documented fiscal year(s), coverage spanning FY2011-FY2025. This keeps the pane grounded in verified chronology even when narrative history research is sparse.
Exhibit: Deterministic timeline anchors
| Date | Event | Category | Impact |
|---|
| 2011 |
Earliest annual financial record in current spine… |
Financial |
Sets the verified start of deterministic coverage… |
| 2025 |
Latest annual financial record in current spine… |
Financial |
Anchors the most recent full-year baseline… |
Source: SEC EDGAR
See fundamentals → ops tab